In vivo evaluation of mebendazole and Ran GTPase inhibition in breast cancer model system

References

• Iranzo J, Martincorena I, Koonin EV. Cancer-mutation network and the number and specificity of driver mutations. Proc. Natl Acad. Sci. USA 115(26), E6010–E6019 (2018).
   PubMed Web of Science ®Google Scholar
• Chitty JL, Filipe EC, Lucas MC, Herrmann D, Cox TR, Timpson P. Recent advances in understanding the complexities of metastasis. F1000Res 7, F1000 Faculty Rev-1169 (2018).
   PubMedGoogle Scholar
• Chan KK, Matchett KB, Mcenhill PM et al. Protein deregulation associated with breast cancer metastasis. Cytokine Growth Factor Rev. 26(4), 415–423 (2015).
   PubMed Web of Science ®Google Scholar
• Sheng C, Qiu J, Wang Y et al. Knockdown of Ran GTPase expression inhibits the proliferation and migration of breast cancer cells. Mol. Med. Rep. 18(1), 157–168 (2018).
   PubMed Web of Science ®Google Scholar
• Desantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J. Clin. 66(1), 31–42 (2016).
   PubMed Web of Science ®Google Scholar
• Feng Y, Spezia M, Huang S et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 5(2), 77–106 (2018).
   PubMed Web of Science ®Google Scholar
• Parker PJ, Kishore U. Editorial: signaling by small GTPases in metastatic disease. Front Cell Dev. Biol. 10, 841572 (2022).
   PubMed Web of Science ®Google Scholar
• El-Tanani M, Platt-Higgins A, Nsairat H et al. Corrigendum to “Development and validation of Ran as a prognostic marker in stage I and stage II primary breast cancer” [Life Sci., 329 (2023) 121964]. Life Sci. 331, 122075 (2023).
   PubMed Web of Science ®Google Scholar
• El-Tanani M, Nsairat H, Mishra V et al. Ran GTPase and its importance in cellular signaling and malignant phenotype. Int. J. Mol. Sci. 24(4), 3065 (2023).
   PubMed Web of Science ®Google Scholar
• Yuen HF, Chan KK, Grills C et al. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin. Cancer Res. 18(2), 380–391 (2012).
   PubMed Web of Science ®Google Scholar
• Costa B, Amorim I, Gärtner F, Vale N. Understanding breast cancer: from conventional therapies to repurposed drugs. Eur. J. Pharm. Sci. 151, 105401 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang L, Bochkur Dratver M, Yazal T et al. Mebendazole potentiates radiation therapy in triple-negative breast cancer. Int. J. Radiat. Oncol. Biol. Phys 103(1), 195–207 (2019).
   PubMed Web of Science ®Google Scholar
• Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in oncology (ReDO) – mebendazole as an anti-cancer agent. eCancerMedicalScience 8, 443 (2014).
   PubMedGoogle Scholar
• Kumar B, Kumar R, Skvortsova I, Kumar V. Mechanisms of tubulin binding ligands to target cancer cells: updates on their therapeutic potential and clinical trials. Curr. Cancer Drug Targets 17(4), 357–375 (2017).
   PubMed Web of Science ®Google Scholar
• Sumimoto Y, Okawa S, Inoue T, Masuda K, Maruyama M, Higaki K. Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: disruption of high crystallinity by utilizing its counter ion. Eur. J. Pharm. Biopharm. 172, 213–227 (2022).
   PubMed Web of Science ®Google Scholar
• Khater D, Nsairat H, Odeh F et al. Design, preparation, and characterization of effective dermal and transdermal lipid nanoparticles: a review. Cosmetics 8(2), 1–43 (2021).
   Google Scholar
• Nsairat H, Khater D, Odeh F et al. Lipid nanostructures for targeting brain cancer. Heliyon 7(9), e07994 (2021).
   PubMed Web of Science ®Google Scholar
• Li Q, Cai T, Huang Y, Xia X, Cole SPC, Cai Y. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials (Basel) 7(6), 122 (2017).
   PubMedGoogle Scholar
• Mehrdadi S. Drug delivery of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) to target brain tumors. Adv. Pharm. Bull. 13(3), 512–520 (2023).
   PubMed Web of Science ®Google Scholar
• Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon 8(5), e09394 (2022).
   PubMed Web of Science ®Google Scholar
• Shakya AK, Al-Sulaibi M, Naik RR, Nsairat H, Suboh S, Abulaila A. Review on PLGA polymer-based nanoparticles with antimicrobial properties and their application in various medical conditions or infections. Polymers 15(17), 1–25 (2023).
   Web of Science ®Google Scholar
• Nsairat H, Ibrahim AA, Jaber AM et al. Liposome bilayer stability: emphasis on cholesterol and its alternatives. J. Liposome Res. 34(1), 178–202 (2024).
   PubMed Web of Science ®Google Scholar
• El-Tanani M, Nsairat H, Aljabali AA, Matalka II, Alkilany AM, Tambuwala MM. Dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer. Expert Opin. Drug Deliv. doi: 10.1080/17425247.2024.2311812 1–16 (2024).
   Web of Science ®Google Scholar
• Jamous YF, Altwaijry NA, Saleem MTS, Alrayes AF, Albishi SM, Almeshari MA. Formulation and characterization of solid lipid nanoparticles loaded with troxerutin. Processes 11(10), 1–18 (2023).
   Web of Science ®Google Scholar
• Pezeshki A, Ghanbarzadeh B, Mohammadi M, Fathollahi I, Hamishehkar H. Encapsulation of vitamin A palmitate in nanostructured lipid carrier (NLC) – effect of surfactant concentration on the formulation properties. Adv. Pharm. Bull. 4(Suppl. 2), 563–568 (2014).
   PubMedGoogle Scholar
• Kim SW, Kim SJ, Langley RR, Fidler IJ. Modulation of the cancer cell transcriptome by culture media formulations and cell density. Int. J. Oncol. 46(5), 2067–2075 (2015).
   PubMed Web of Science ®Google Scholar
• Lee DY, Lee SY, Yun SH et al. Review of the current research on fetal bovine serum and the development of cultured meat. Food Sci. Anim. Resour. 42(5), 775–799 (2022).
   PubMed Web of Science ®Google Scholar
• Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. Int. J. Mol. Sci. 22(23), 1–30 (2021).
   Web of Science ®Google Scholar
• Justus CR, Leffler N, Ruiz-Echevarria M, Yang LV. In vitro cell migration and invasion assays. J. Vis. Exp. doi: 10.3791/51046(88) (2014).
   PubMed Web of Science ®Google Scholar
• Martinez-Madrid B, Donnez J, Eyck A-S, Veiga-Lopez A, Dolmans M-M, Van Langendonckt A. Chick embryo chorioallantoic membrane (CAM) model: a useful tool to study short-term transplantation of cryopreserved human ovarian tissue. Fertil. Steril. 91, 285–292 (2008).
   PubMed Web of Science ®Google Scholar
• Tahergorabi Z, Khazaei M. A review on angiogenesis and its assays. Iran J. Basic Med. Sci. 15(6), 1110–1126 (2012).
   PubMed Web of Science ®Google Scholar
• Eh Suk VR, Mohd Latif F, Teo YY, Misran M. Development of nanostructured lipid carrier (NLC) assisted with polysorbate nonionic surfactants as a carrier for l-ascorbic acid and Gold Tri.E 30. J. Food Sci. Technol. 57(9), 3259–3266 (2020).
   PubMed Web of Science ®Google Scholar
• Yang S, Gong P, Pan J et al. Pediococcus pentosaceus xy46 can absorb zearalenone and alleviate its toxicity to the reproductive systems of male mice. Microorganisms 7(8), 1–18 (2019).
   Web of Science ®Google Scholar
• Deng R, Wang SM, Yin T et al. Dimethyl sulfoxide suppresses mouse 4T1 breast cancer growth by modulating tumor-associated macrophage differentiation. J. Breast Cancer 17(1), 25–32 (2014).
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang JJ, Huang XY. Mouse models for tumor metastasis. Methods Mol. Biol. 928, 221–228 (2012).
   PubMedGoogle Scholar
• Hong X, Liu Y, Hu G et al. EBAG9 inducing hyporesponsiveness of T cells promotes tumor growth and metastasis in 4T1 murine mammary carcinoma. Cancer Sci. 100(5), 961–969 (2009).
   PubMed Web of Science ®Google Scholar
• Rajeh MA, Kwan YP, Zakaria Z, Latha LY, Jothy SL, Sasidharan S. Acute toxicity impacts of Euphorbia hirta L extract on behavior, organs body weight index and histopathology of organs of the mice and Artemia salina. Pharmacognosy Res. 4(3), 170–177 (2012).
   PubMedGoogle Scholar
• Burggren W, Rojas Antich M. Angiogenesis in the avian embryo chorioallantoic membrane: a perspective on research trends and a case study on toxicant vascular effects. J. Cardiovasc. Dev. Dis. 7(4), 56 (2020).
   PubMed Web of Science ®Google Scholar
• Chaudhary S, Garg T, Murthy RS, Rath G, Goyal AK. Development, optimization and evaluation of long chain nanolipid carrier for hepatic delivery of silymarin through lymphatic transport pathway. Int. J. Pharm. 485(1–2), 108–121 (2015).
   PubMed Web of Science ®Google Scholar
• Northcott PA, Jones DT, Kool M et al. Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 12(12), 818–834 (2012).
   PubMed Web of Science ®Google Scholar
• Wang HY, Yang SL, Liang HF, Li CH. HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK/ERK and PI3K/Akt pathways. Int. J. Mol. Sci. 15(3), 3507–3518 (2014).
   PubMed Web of Science ®Google Scholar
• El-Tanani M, Nsairat H, Aljabali AA et al. Role of mammalian target of rapamycin (mTOR) signalling in oncogenesis. Life Sci. 323, 121662 (2023).
   PubMed Web of Science ®Google Scholar
• Williamson T, Mendes TB, Joe N, Cerutti JM, Riggins GJ. Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer. Endocr. Relat. Cancer 27(3), 123–136 (2020).
   PubMed Web of Science ®Google Scholar
• Mohi-Ud-Din R, Chawla A, Sharma P et al. Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects. Eur. J. Med. Res. 28(1), 345 (2023).
   PubMed Web of Science ®Google Scholar